Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.40 |
| ▸ | DRD3 | P35462 | 6/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 3/20 | 0.37 |
| ▸ | DRD4 | P21917 | 3/20 | 0.37 |
| ▸ | DRD5 | P21918 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14734035 | 0.88 | DRD2 (0.45) | DRD2DRD3SIGMAR1SMN1; SMN2 | |
| SCHEMBL22521632 | 0.86 | GNAI3 (0.49) | SIGMAR1 | |
| SCHEMBL10284368 | 0.86 | GBA1 (0.38) | DRD2DRD3SIGMAR1DRD1DRD4 | |
| SCHEMBL15998447 | 0.84 | SMN1; SMN2 (0.38) | SMN1; SMN2 | |
| SCHEMBL4375810 | 0.81 | HTR2A (0.34) | DRD2SIGMAR1 | |
| SCHEMBL438485 | 0.81 | RORC (0.37) | SIGMAR1SMN1; SMN2 | |
| SCHEMBL10284374 | 0.81 | RORC (0.31) | — | |
| SCHEMBL4375813 | 0.80 | HTR2A (0.33) | DRD2 | |
| SCHEMBL14116869 | 0.78 | FGFR1 (0.36) | SMN1; SMN2 | |
| SCHEMBL24009189 | 0.77 | DRD2 (0.43) | DRD2DRD3SIGMAR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-9273055-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-9249147-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2966076-A1 | NOVEL TYROSINE KINASE INHIBITORS | ChemBridge Corporation (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2262807-B1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE CORP (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-02-05 | — | — | US | disclosed |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-01-08 | — | — | US | disclosed |
| US-8822500-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-8815906-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2013-02-28 | — | — | US | disclosed |
| WO-2012037155-A2 | TYROSINE KINASE INHIBITORS | GTX, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2009117097-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2008021369-A2 | TRICYCLIC COMPOUNDS AND ITS USE AS TYROSINE KINASE MODULATORS | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | DRD2 4719/4885DRD3 4717/4885SIGMAR1 3569/4885 |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | DRD2 4827/4885DRD3 4792/4885SIGMAR1 4733/4885 |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | DRD2 4785/4885DRD3 4761/4885SIGMAR1 3482/4885 |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | DRD2 4785/4885DRD3 4761/4885SIGMAR1 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.